| 1 |
29721381 |
10.1080/2162402X.2017.1423183 |
2022 |
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. |
MS4A1 |
| 2 |
34743199 |
10.1038/s41416-021-01611-7 |
2022 |
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles. |
MS4A1 |
| 3 |
36030374 |
10.1002/eji.202250037 |
2022 |
IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies. |
MS4A1 |
| 4 |
31682318 |
10.1002/cyto.b.21852 |
2021 |
CD20-positive primary nasal peripheral T-cell lymphoma: An analysis of one case and review of the literature. |
MS4A1 |
| 5 |
31907371 |
10.1038/s41419-019-2210-0 |
2021 |
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. |
MS4A1 |
| 6 |
32585766 |
10.1002/1878-0261.12753 |
2021 |
Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma. |
MS4A1 |
| 7 |
32589730 |
10.1182/bloodadvances.2020001696 |
2021 |
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. |
MS4A1 |
| 8 |
33686443 |
10.2340/00015555-3775 |
2021 |
Role of B-cells in Mycosis Fungoides. |
MS4A1 |
| 9 |
34061467 |
10.1002/cam4.3983 |
2021 |
A new score including CD43 and CD180: Increased diagnostic value for atypical chronic lymphocytic leukemia. |
MS4A1 |
| 10 |
34252986 |
10.1111/cas.15055 |
2021 |
Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20. |
MS4A1 |
| 11 |
31669559 |
10.1016/j.exphem.2019.10.004 |
2020 |
Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies. |
MS4A1 |
| 12 |
32210425 |
10.1371/journal.pone.0229170 |
2020 |
CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. |
MS4A1 |
| 13 |
32314054 |
10.1007/s00428-020-02776-x |
2020 |
CD20-positive extranodal NK/T cell lymphoma: clinicopathologic and prognostic features. |
MS4A1 |
| 14 |
32669656 |
10.1038/s41598-020-68360-0 |
2020 |
Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20<sup>+</sup> B-cell lymphoma: a multicenter, randomized, double-blind, parallel-controlled study. |
MS4A1 |
| 15 |
32792392 |
10.1126/science.abb8008 |
2020 |
Binding mechanisms of therapeutic antibodies to human CD20. |
MS4A1 |
| 16 |
28887496 |
10.1038/s41598-017-11389-5 |
2019 |
Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma. |
MS4A1 |
| 17 |
30273194 |
10.1097/PAS.0000000000001168 |
2019 |
Age and CD20 Expression Are Significant Prognostic Factors in Human Herpes Virus-8-negative Effusion-based Lymphoma. |
MS4A1 |
| 18 |
27528699 |
10.1158/1078-0432.CCR-16-1275 |
2018 |
Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. |
MS4A1 |
| 19 |
28303902 |
10.1038/icb.2017.18 |
2018 |
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells. |
MS4A1 |
| 20 |
28442514 |
|
2018 |
CD3 and CD20 Immunohistochemical Staining Patterns of Bone Marrow-Infiltrating Malignant Lymphoma Cells. |
MS4A1 |
| 21 |
29489886 |
10.1371/journal.pone.0193098 |
2018 |
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. |
MS4A1 |
| 22 |
29567884 |
10.4103/IJPM.IJPM_267_17 |
2018 |
Utility of CD200 expression and CD20 antibody binding capacity in differentiating chronic lymphocytic leukemia from other chronic lymphoproliferative disorders. |
MS4A1 |
| 23 |
26119874 |
10.1002/hon.2244 |
2017 |
Low CD23 expression correlates with high CD38 expression and the presence of trisomy 12 in CLL. |
MS4A1 |
| 24 |
26459310 |
10.1007/s13277-015-4205-5 |
2017 |
CD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 cases. |
MS4A1 |
| 25 |
26585505 |
10.1016/j.jconrel.2015.11.015 |
2017 |
Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody. |
MS4A1 |
| 26 |
27840885 |
10.2340/00015555-2576 |
2017 |
Primary Cutaneous T-cell Lymphoma with Aberrant Expression of CD20. |
MS4A1 |
| 27 |
28830887 |
10.1182/blood-2016-08-736066 |
2017 |
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. |
MS4A1 |
| 28 |
24898664 |
10.3109/10428194.2014.927455 |
2016 |
The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. |
MS4A1 |
| 29 |
25098425 |
10.3109/10428194.2014.951849 |
2016 |
High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages. |
MS4A1 |
| 30 |
26013593 |
10.1002/cyto.b.21253 |
2016 |
Consistent, multi-instrument single tube quantification of CD20 in antibody bound per cell based on CD4 reference. |
MS4A1 |
| 31 |
26381030 |
10.1097/DAD.0000000000000323 |
2016 |
Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder: A Case Report. |
MS4A1 |
| 32 |
26398317 |
10.3892/ijo.2015.3170 |
2016 |
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy. |
MS4A1 |
| 33 |
26907258 |
10.3390/ijms17020250 |
2016 |
Assessment of Radiation Induced Therapeutic Effect and Cytotoxicity in Cancer Patients Based on Transcriptomic Profiling. |
MS4A1 |
| 34 |
27090891 |
10.1186/s13045-016-0270-5 |
2016 |
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. |
MS4A1 |
| 35 |
24467775 |
10.1111/cup.12299 |
2015 |
Mycosis fungoides with CD20 expression: report of two cases and review of the literature. |
MS4A1 |
| 36 |
25382151 |
10.1111/bjh.13205 |
2015 |
Current status of antibody therapy in ALL. |
MS4A1 |
| 37 |
25449106 |
10.1002/ijc.29366 |
2015 |
CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes. |
MS4A1 |
| 38 |
25517315 |
10.4161/mabs.32106 |
2015 |
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. |
MS4A1 |
| 39 |
26299072 |
10.7754/clin.lab.2014.140602 |
2015 |
Establishment and Characterization of a CD20-Positive NK/T-Cell Lymphoma Cell Line. |
MS4A1 |
| 40 |
24147568 |
10.1111/cas.12307 |
2014 |
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity. |
MS4A1 |
| 41 |
22665052 |
10.1038/onc.2012.219 |
2013 |
TGF-β-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1/CD20. |
MS4A1 |
| 42 |
22961721 |
10.1002/cyto.b.21038 |
2013 |
Flow cytometry CD45-negative B-NHL: a case report of a diffuse large B-cell lymphoma without extranodal involvement. |
MS4A1 |
| 43 |
23031227 |
10.1186/1746-1596-7-133 |
2013 |
CD20-positive NK/T-cell lymphoma with indolent clinical course: report of case and review of literature. |
MS4A1 |
| 44 |
24145652 |
10.1097/PAS.0000000000000091 |
2013 |
CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact. |
MS4A1 |
| 45 |
21630262 |
10.1002/ijc.26209 |
2012 |
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. |
MS4A1 |
| 46 |
22167754 |
10.1182/blood-2011-07-363820 |
2012 |
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. |
MS4A1 |
| 47 |
22664043 |
10.1179/102453312X13221316477741 |
2012 |
CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. |
MS4A1 |
| 48 |
22843692 |
10.1074/jbc.M112.374751 |
2012 |
Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicity. |
MS4A1 |
| 49 |
21348573 |
10.3109/10428194.2011.559668 |
2011 |
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. |
MS4A1 |
| 50 |
21721452 |
|
2011 |
Utilization of a scoring system for diagnosis of chronic lymphocytic leukemia in Thai patients. |
MS4A1 |
| 51 |
19000453 |
|
2010 |
[Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's Lymphoma]. |
MS4A1 |
| 52 |
19811331 |
10.1080/10428190903064824 |
2010 |
Immunophenotyping of mature B-cell non Hodgkin lymphoma involving bone marrow and peripheral blood: critical analysis and insights gained at a tertiary care cancer hospital. |
MS4A1 |
| 53 |
20350657 |
10.1053/j.seminhematol.2010.01.001 |
2010 |
CD20 as a target for therapeutic type I and II monoclonal antibodies. |
MS4A1 |
| 54 |
20660329 |
10.1309/AJCP7YLDTJPLCE5F |
2010 |
Double-Hit mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. |
MS4A1 |
| 55 |
20815894 |
10.1186/1756-9966-29-121 |
2010 |
Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene tranfected T cells. |
MS4A1 |
| 56 |
19029441 |
10.1182/blood-2008-09-177469 |
2009 |
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. |
MS4A1 |
| 57 |
19054557 |
10.1016/j.leukres.2008.10.013 |
2009 |
Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. |
MS4A1 |
| 58 |
19136769 |
10.4103/0377-4929.44952 |
2009 |
CD20 positivity in classical Hodgkin's lymphoma: Diagnostic challenge or targeting opportunity. |
MS4A1 |
| 59 |
19207312 |
10.1111/j.1365-2303.2008.00616.x |
2009 |
Analysis of CD20 alone could be misleading in lineage determination of B-cell lymphomas: a case of CD20 negative diffuse large B-cell lymphoma in abdominal effusion. |
MS4A1 |
| 60 |
19211644 |
10.3324/haematol.2008.001024 |
2009 |
CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. |
MS4A1 |
| 61 |
19246561 |
10.1182/blood-2008-08-175208 |
2009 |
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. |
MS4A1 |
| 62 |
19276251 |
10.1158/1078-0432.CCR-08-1403 |
2009 |
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. |
MS4A1 |
| 63 |
19513512 |
10.3892/or_00000413 |
2009 |
Dual functional molecular imaging probe targeting CD20 with PET and optical imaging. |
MS4A1 |
| 64 |
19513562 |
10.3892/ijo_00000323 |
2009 |
Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. |
MS4A1 |
| 65 |
19769942 |
10.1016/j.bbrc.2009.09.059 |
2009 |
Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. |
MS4A1 |
| 66 |
17712791 |
10.1002/ajh.21022 |
2008 |
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. |
MS4A1 |
| 67 |
18263793 |
10.1182/blood-2007-11-126243 |
2008 |
FMC7 is an epitope of CD20. |
MS4A1 |
| 68 |
18346788 |
10.1016/j.molimm.2008.01.034 |
2008 |
Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. |
MS4A1 |
| 69 |
18426802 |
10.1074/jbc.M708459200 |
2008 |
Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. |
MS4A1 |
| 70 |
18652276 |
|
2008 |
[CD20 antigen of Hodgkin and Reed-Sternberg cells as possible prognostic factor in patients with Hodgkin's lymphoma--preliminary reports]. |
MS4A1 |
| 71 |
16923555 |
10.1080/10428190600565354 |
2007 |
Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation? |
MS4A1 |
| 72 |
16923582 |
10.1080/10428190600581625 |
2007 |
CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-). |
MS4A1 |
| 73 |
17041886 |
10.1002/cncr.22251 |
2007 |
Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. |
MS4A1 |
| 74 |
17336267 |
10.1016/j.bbrc.2007.02.053 |
2007 |
Dynamic interplay between the neutral glycosphingolipid CD77/Gb3 and the therapeutic antibody target CD20 within the lipid bilayer of model B lymphoma cells. |
MS4A1 |
| 75 |
18006839 |
10.1158/0008-5472.CAN-07-1252 |
2007 |
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. |
MS4A1 |
| 76 |
16280659 |
10.1097/01.pai.0000137363.36091.7e |
2006 |
CD5-positive B-cell neoplasms of indeterminate immunophenotype: a clinicopathologic analysis of 26 cases. |
MS4A1 |
| 77 |
16285718 |
10.1021/bi0511078 |
2006 |
Isolation and characterization of the B-cell marker CD20. |
MS4A1 |
| 78 |
16498670 |
10.1002/cyto.b.20091 |
2006 |
Unsupervised immunophenotypic profiling of chronic lymphocytic leukemia. |
MS4A1 |
| 79 |
17000895 |
10.1177/1076029606293439 |
2006 |
Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report. |
MS4A1 |
| 80 |
15927668 |
10.1016/j.leukres.2004.11.021 |
2005 |
GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes. |
MS4A1 |
| 81 |
14582135 |
10.1002/cyto.b.10049 |
2004 |
Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). |
MS4A1 |
| 82 |
15073603 |
10.1038/modpathol.3800129 |
2004 |
TIA-1 expression in hairy cell leukemia. |
MS4A1 |
| 83 |
15480506 |
10.1267/nukl04050171 |
2004 |
[Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma]. |
MS4A1 |
| 84 |
12393541 |
10.1182/blood-2002-06-1761 |
2003 |
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. |
MS4A1 |
| 85 |
12835728 |
10.1038/sj.leu.2402978 |
2003 |
A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. |
MS4A1 |
| 86 |
14608903 |
10.1309/FNGC-YEMJ-E3MA-E5L2 |
2003 |
Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. |
MS4A1 |
| 87 |
11697493 |
10.3109/10428190109099325 |
2002 |
Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density. |
MS4A1 |
| 88 |
11857591 |
|
2002 |
Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification. |
MS4A1 |
| 89 |
11939741 |
10.1309/urtd-7md9-u8n1-c60q |
2002 |
Discrepancies in the immunophenotype of lymphoma cells in samples obtained simultaneously from different anatomic sites. |
MS4A1 |
| 90 |
12447967 |
10.1002/ajh.10224 |
2002 |
CD3-negative, CD20-positive T-cell prolymphocytic leukemia: case report and review of the literature. |
MS4A1 |
| 91 |
11211615 |
10.1309/VWTK-XYT5-D0DK-06HQ |
2001 |
Diagnostic usefulness of CD23 and FMC-7 antigen expression patterns in B-cell lymphoma classification. |
MS4A1 |
| 92 |
11242795 |
10.1309/F5WE-K2T8-BT9D-Q56D |
2001 |
Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. |
MS4A1 |
| 93 |
11309819 |
10.1002/cyto.1071 |
2001 |
Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses. |
MS4A1 |
| 94 |
11706075 |
10.1038/modpathol.3880448 |
2001 |
Leukemic mantle cell lymphoma: clinical and pathologic spectrum of twenty-three cases. |
MS4A1 |
| 95 |
9579603 |
10.1002/(sici)1097-0320(19980415)34:2<71::aid-cyto2>3.0.co;2-f |
1998 |
FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20. |
MS4A1 |
| 96 |
8701937 |
10.1093/ajcp/106.1.78 |
1996 |
CD20 (pan-B cell antigen) expression on bone marrow-derived T cells. |
MS4A1 |
| 97 |
8816400 |
|
1996 |
Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. |
MS4A1 |
| 98 |
3871452 |
|
1985 |
Human B cell development. II. Subpopulations in the human fetus. |
MS4A1 |
Datasets
Models
